Pharma's Preferred Patent Reforms May Be Too Expensive
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Schumer supports exempting Rx industry from inter partes review, but tells BIO conference that legislators must find $1.2 billion to enact it; calls for industry code of conduct on pricing.
You may also be interested in...
Will Slew of Patent Bills Lower Drug Prices?
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.
US Supreme Court’s EPA Ruling Expected To Have Limited Impact On FDA Regulations
Court restricts EPA’s ability to regulate greenhouse gas emissions saying agency must have “clear congressional authorization” to address “major questions.” Decision is not likely to pose a problem for the FDA unless it were to regulate something new, attorneys say.
Patient-Focused Drug Development Guidance: Determining When A Clinical Outcome Assessment Is Appropriate
A US FDA draft guidance on selecting and developing fit-for-purpose clinical outcome assessments specifies the evidence that can be provided to support using a COA in a particular context.